Laurion Capital Management’s UroGen Pharma URGN Stock Holding History

Laurion Capital Management’s Portfolio URGN Stock Details URGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-160,600	Closed	-$2.69M	–	595
2024 Q2	$2.69M	Sell	160,600 -90,000	-36%	-$1.28M	0.03%	197
2024 Q1	$3.76M	Hold	250,600	–	–	0.03%	282
2023 Q4	$3.76M	Sell	250,600 -130,000	-34%	-$1.69M	0.03%	258
2023 Q3	$5.33M	Buy	380,600 +11,495	+3%	+$185K	0.03%	275
2023 Q2	$3.82M	Sell	369,105 -11,495	-3%	-$127K	0.02%	276
2023 Q1	$3.52M	Hold	380,600	–	–	0.02%	253
2022 Q4	$3.38M	Hold	380,600	–	–	0.02%	285
2022 Q3	$3.17M	Hold	380,600	–	–	0.02%	290
2022 Q2	$3.12M	Buy	+380,600	New	+$2.61M	0.05%	197
2018 Q1	–	Sell	-47,473	Closed	-$1.77M	–	1717
2017 Q4	$1.77M	Buy	+47,473	New	+$1.69M	0.01%	814

Other funds holding URGN

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Laurion Capital Management's URGN Position: Q3 2024 in Review

Laurion Capital Management sold out of UroGen Pharma (URGN) in Q3 2024, closing a stake of 160,600 shares — an estimated $2.69M sold.

Laurion Capital Management first reported a position in URGN in Q4 2017 and held it in 10 quarters. The position peaked at $5.33M in Q3 2023. 128 funds tracked by Wall St. Rank hold URGN as of Q3 2024.

Laurion Capital Management reported no remaining UroGen Pharma position as of Q3 2024 after selling out during the quarter.
Laurion Capital Management sold 160,600 UroGen Pharma shares in Q3 2024, an estimated $2.69M.
Laurion Capital Management first reported a position in UroGen Pharma in Q4 2017 and held it in 10 quarters.
Laurion Capital Management's UroGen Pharma position peaked at $5.33M in Q3 2023.
128 funds tracked by Wall St. Rank held UroGen Pharma as of Q3 2024.

Based on Laurion Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.